Senior Director, Pharmacology

As Senior Director at Y-mAbs, you will be responsible for defining non–clinical pharmacology strategies for new and existing projects. This includes our novel and differentiating 2-step pre-targeting Radioimmunotherapy (pRIT) platform.

https://uhc.dk/wp-content/uploads/2023/03/Senior_Director_Pharmacology_y_mab-1.mp4

You will be covering early work to support lead candidate selection, mode of action/proof of concept in vitro and in animal tumor models as well as pharmacology support to post-marketing activities in close collaboration with Early Discovery/Pharmacology, Toxicology, Assay and Clinical Development. You will represent translational medicine in cross-functional project teams, including clinical trial teams, and ensure a focused and fast development path into patients.

Y-mAbs is mainly oriented to pediatric cancer, and as Senior Director, you will be working around their SADA studies. The SADA technology utilizes a targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs to radiate the tumor.

Furthermore, you will be responsible for authoring/reviewing submissions to the authorities (FDA/EMA), developing portfolio strategies, managing budgets, and forecasts, be in charge of CRO oversight and agreements.

With direct report to Chief Scientific Officer.

Other responsibilities include:

• Participate in the strategic sub team for new SADA molecule development within radioimmunotherapy space
• Participate in the team for the development of new imaging agents and potential companion diagnostics
• Patent strategy – alignment with external and internal stakeholders
• Co-lead generation of documents for regulatory submissions focusing on pharmacology sections (e.g., IND/CTA)
• Work cross organizational with the Theragnostic Group in collaboration with the Director for Toxicology
• Drive innovation in terms of early project maturation, mode of action/mechanistic investigations as well as developing novel assays for screening and preclinical validation of Proof of Principle

Your qualifications are a minimum of 7 years of relevant and significant preclinical research experience from the pharmaceutical/biotechnological industry. You have in-depth immunological understanding, early target assessment and disease understanding; and preferably experience with oncology models. You have a track record of drug submissions/approvals, a strong scientific mindset, and practical experience with non-clinical drug development and planning and conducting non-clinical projects and programs. You have experience with health authority interactions and submissions and can navigate in a cross-functional company.

You have an M.Sc./ degree in Life Science, Pharmacology, Molecular Biology, and/or Veterinary or a related scientific field.

Y-mAbs offers an exciting career opportunity in a young, growing international company that fosters an open, trusting atmosphere. Y-mAbs provides significant professional and personal growth opportunities for its employees and is committed to helping employees balance work life and personal time.

Traveling: Approx. 10 days per year.

Domicile: In commuting distance of the office in Hørsholm.

For more details about the job or the company, please contact Director Life Science Gert Vium Andersen, Unique Human Capital on M: +45 42 95 08 83. All applications must be in English and are treated confidentially.